Topical taurine bromamine, a new candidate in the treatment of moderate inflammatory acne vulgaris: a pilot study.
Taurine bromamine (TauBr), the product of taurine and hypobromous acid (HOBr), exerts anti-inflammatory and antibacterial properties. Recently we have shown that Propionibacterium acnes, a potential pathogenic agent of acne, is extremely sensitive to TauBr. As topical antibiotics are associated with the emergence of resistant bacteria, TauBr seems to be a good candidate for topical therapy for acne vulgaris. In our double blind investigation, the efficacy and safety of 3.5 mM TauBr cream was evaluated. 1% Clindamycin gel (Clindacin T), one of the most common topical agents in the treatment of acne vulgaris, was used as a control. Forty patients with mild to moderate inflammatory facial acne vulgaris were randomly treated with either TauBr or clindamycin for 6 weeks, twice-a-day. More than 80% of the patients markedly improved with both treatments, without any adverse effects observed. Both TauBr and clindamycin produced a significant reduction in inflammatory skin lesion counts (papules/ pustules). After 6 weeks, comparable reductions of acne lesions, 65% and 68%, were observed in the TauBr and clindamycin groups, respectively. In conclusion, these data support our concept that TauBr can be used as a topical agent in the treatment of acne vulgaris, especially in patients who have already developed antibiotic resistance.
Department of Immunology Jagiellonian University Medical College, Krakow, Poland. mmmarcin@cyf-kr.edu.pl
Janusz
J
Marcinkiewicz
Anna
A
Wojas-Pelc
Maria
M
Walczewska
Sylwia
S
Lipko-Godlewska
Renata
R
Jachowicz
Aldona
A
Maciejewska
Anna
A
Białecka
Andrzej
A
Kasprowicz
D000152:Acne Vulgaris / Q000188:drug therapy* / Q000473:pathology; D000287:Administration, Topical; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D002981:Clindamycin / Q000008:administration & dosage; D003879:Dermatologic Agents / Q000008:administration & dosage*; D004311:Double-Blind Method; D004643:Emollients; D005145:Face; D005260:Female; D005782:Gels; D006801:Humans; D008297:Male; D010865:Pilot Projects; D013654:Taurine / Q000008:administration & dosage / Q000031:analogs & derivatives*
D000900:Anti-Bacterial Agents; D003879:Dermatologic Agents; D004643:Emollients; D005782:Gels; D013654:Taurine; D002981:Clindamycin; C052954:N-bromotaurine